Loading stock data…
Wave Life Sciences Ltd (WVE)
$5.68-0.15 (-2.57%)
After Hours$5.78+0.10 (+1.80%)· Last close Jun 29
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Wave Life Sciences Ltd. in the Healthcare sector is trading at $5.68 with a market capitalization of $1.1B. Wall Street consensus targets $21.94 (16 analysts), implying a +286.2% move over the next 12 months. The stock is currently near its 52-week low of $5.02, remaining 41.7% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +286.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $38.25M↑ | $17.25M↑ | $7.61M↓ | $8.70M↓ | $9.18M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$31.30M↑ | -$56.47M↓ | -$56.35M↓ | -$52.76M↓ | -$49.80M |
| Net Income | -$26.09M↑ | -$53.18M↑ | -$53.85M↓ | -$50.47M↓ | -$46.88M |
Peer Comparison
JNJUNHPFE
Fundamentals
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multipl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.12B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-35.88%
Volume
Today's trading volume
2.69M
Recent News
Wave Life Sciences (WVE) Upgraded to Buy: Here's Why
Wave Life Sciences (WVE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?
Intellia Therapeutics (NTLA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Is Wave Life Sciences Ltd. (WVE) A Good Stock To Buy Now?
Is WVE a good stock to buy? We came across a bullish thesis on Wave Life Sciences Ltd. on Biotech Distilled’s Substack. In this article, we will summarize the bulls’ thesis on WVE. Wave Life Sciences Ltd.’s share was trading at $5.70 as of June 8th. Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and […]
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter
This clinical-stage biotech develops precision genetic medicines for neurological and hepatic disorders via its PRISM platform.
Should WVE-006’s RNA-Editing AAT Data Shift the Risk-Reward Calculus for Wave Life Sciences (WVE) Investors?
Earlier this month, Wave Life Sciences reported updated RestorAATion-2 data showing its RNA-editing candidate WVE-006 reduced harmful Z-AAT and restored protective M-AAT to MZ-like levels in alpha-1 antitrypsin deficiency, with convenient subcutaneous dosing and a favorable safety profile. The data also showed that WVE-006 enabled rapid, natural surges in AAT during acute inflammatory episodes, suggesting restoration of the body’s normal capacity to boost lung-protective protein when...